Jan. 21 - Trump rescinds Biden healthcare orders | FTC gets Welsh Carson to limit anesthesia influence

ACA enrollment breaks records again in 2025; Welsh Carson agrees to pare back anesthesia market power to avoid new FTC suit; Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.

View online | Signup

Daily Dive

Jan. 21, 2025 | Today’s news and insights for healthcare leaders

TRENDLINE

The Evolution of Electronic Health Records

EHRs are the bedrock of modern healthcare, enabling data sharing across healthcare entities while driving innovation through big data & AI tools. Explore efforts to streamline their management in this Trendline.

Trump reverses Biden healthcare directives, withdraws from WHO in first executive orders

The rescinded orders include directives boosting the Affordable Care Act exchanges, coordinating the government’s COVID-19 response and overseeing artificial intelligence tools.

ACA enrollment breaks records again in 2025

About 24.2 million people signed up for Affordable Care Act plans during the open enrollment period for 2025, with huge increases in major Republican-led states.

Welsh Carson agrees to pare back anesthesia market power to avoid new FTC suit

Antitrust regulators have reached a deal with Welsh, Carson, Anderson and Stowe that doesn’t penalize the private equity firm for rolling up the market for anesthesia services in Texas, but tries to prevent it from happening again.

The invisible edge: an introduction to AI-enabled data migration

AI transforms medical data migration: faster, smarter and ready for the future of healthcare.

Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.

Novo sells semaglutide as Ozempic, Rybelsus and Wegovy. The CMS will treat the different forms as a single product in price talks.

From Our Library

Playbook

What We’re Reading

Bloomberg